US6410546B1ExpiredUtility

Use of MKC-442 in combination with other antiviral agents

30
Assignee: TRIANGLE PHARMACEUTICALS INCPriority: Apr 7, 1997Filed: Apr 7, 1998Granted: Jun 25, 2002
Est. expiryApr 7, 2017(expired)· nominal 20-yr term from priority
Inventors:Phillip A. FurmanCary P. MoxhamDavid W. BarryKatyna Borroto-Esoda
A61K 45/06A61P 31/18A61K 31/513A61K 31/505A61P 37/04
30
PatentIndex Score
3
Cited by
46
References
8
Claims

Abstract

Use of MKC-442 in combination with other antiviral agents for the treatment of patients infected with HIV is disclosed.

Claims

exact text as granted — not AI-modified
We claim:  
     
       1. A method for the treatment of a patient infected with HIV, comprising administering an effective treatment amount of MKC-442 or its pharmaceutically acceptable salt in combination or alternation with a compound selected from the group consisting of abacavir, FTC or d4T or its pharmaceutically acceptable salt. 
     
     
       2. The method of  claim 1 , wherein the compound is FTC. 
     
     
       3. A pharmaceutical composition for the treatment of a patient infected with HIV, comprising an effective treatment amount of MKC-442 or its pharmaceutically acceptable salt in combination or alternation with a compound selected from the group consisting of abacavir, FTC or d4T or its pharmaceutically acceptable salt. 
     
     
       4. The composition of  claim 3 , wherein the compound is FTC. 
     
     
       5. The method of  claim 1 , wherein the compound is abacavir. 
     
     
       6. The composition of  claim 3 , wherein the compound is abacavir. 
     
     
       7. The method of  claim 1 , wherein the compound is d4T. 
     
     
       8. The composition of  claim 3 , wherein the compound is d4T.

Join the waitlist — get patent alerts

Track US6410546B1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.